CANCER PROSTATE

TREATMENT RESPONSE ON THE LEVEL OF PROSTATE SPECIFIC ANTIGEN (PSA)

Abstract

Prostate specific antigen was identified and characterized first time in 1977. There
is no doubt that the PSA has significant role in prostate cancer diagnosis with help of Digital
Rectal Examination and biopsy. Study design: This study was designed to assess the level of
PSA in prostate cancer patients before and after the treatment given to patients. To determine
the specific and precise finding regarding the tumors stages, the cancer biomarkers are handy
and helpful. For this purpose researchers monitor changes in the cell on chromosomal level by
comparing primary tumor with secondary tumor. The prostate-specific gene kallikrein 3 (KLK3),
encodes PSA located on chromosome 19q13.4. KLK2 and KLK4 genes are also present here
which are present in a family of fifteen closely related serine proteases. Setting: Allied Hospital,
Faisalabad. Period: Jan 2014 to Dec 2014. Material and methods: We use the PSA (Human)
CLIA Kit which is a solid phase two site immunoassay. One antibody was coated on the surface
of the microtiter wells and another antibody (used as a tracer) was labeled with horseradish
peroxidase. The PSA molecules present in the standard solution or serum were “sandwiched”
between the two antibodies. Results: All prostate cancer patients had highly variable serum
PSA values ranging from 12.90 ng/mL to 193.5 ng/mL. The post treatment PSA analysis
revealed that the increase level of PSA (15%) which showed that the PSA level increased after
the treatment. Whereas in all other 17 patients the PSA level was found to decreased. Our study
also shows that sometime PSA level is increased by non-cancer associated benign prostatic
hyperplasia (BPH), prostatitis, medications and environment and diet alterations. Conclusions:
This study indicated that PSA serum level has a useful role in diagnosis of prostate cancer.